Valencell is a developer of AI-based medical sensors and wearable health monitoring technology. The company designs photoplethysmography (PPG) sensors that calibrate multiple health vitals including blood pressure, heart rate, VO2 max, step count, and respiration rate for the wearable and hearable industry. Valencell's technology enables continuous, non-invasive monitoring supporting applications in cardiac disease management, remote patient monitoring, and value-based care. The company licenses its sensor technology to wearable manufacturers and develops FDA-cleared medical devices for cuffless blood pressure monitoring. Founded in 2006 and headquartered in Raleigh, North Carolina, Valencell has raised approximately $37.6 million in Series E funding from investors including True Ventures, TDF Ventures, Best Buy, Halma, and Sonion.
Valencell
Series EValencell is a developer of AI-based medical sensors and wearable health monitoring technology. The company designs photoplethysmography (PPG) sensors that calibrate multiple health vitals including blood pressure, heart rate, VO2 max, step count, and respiration rate for the wearable and hearable industry. Valencell's technology enables continuous, non-invasive monitoring supporting applications in cardiac disease…
About
Business model
Wearable Technology > Technology Enablers > Sensors,
Disease Self Management > Body Health Parameters > Monitoring > Body Chemistry > Device,
Healthcare IT > Value Based Care > Remote Monitoring > Hardware > Wearables > Vitals Monitoring > Blood Pressure,
Cardiac and Vascular Disorders > Medical Devices > Monitoring Devices > Blood Gas Levels,
Sensors > Generic Sensor Developers > Biological > Body Vitals,
Plug and Play Tech Center Batches > Cleveland > Batch 1
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ See who's investing in Semiconductors — full fund directory with check size and geography.